Evidence map›Paper›PMID 42898833›Full record

ArticleOpen forum infectious diseases2026

A Whole-blood Transcriptional Signature Associated With Obstructive Post-tuberculosis Lung Disease.

Renee E Newby, Lucy Kijaro, Kimberly A Dill-McFarland, Lilian N Njagi, Wilfred B Murithi, Zipporah Mwongera, Moeko Agata, Jodi Byers, Glenna J Peterson, Kevin P Fennelly and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Renee E NewbyDepartment of Medicine, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-9840-2977
Lucy KijaroCentre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya.
Kimberly A Dill-McFarlandDepartment of Medicine, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-1481-7065
Lilian N NjagiCentre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID https://orcid.org/0000-0002-5067-0788
Wilfred B MurithiCentre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID https://orcid.org/0000-0002-4495-2957
Zipporah MwongeraCentre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya.
Moeko AgataDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Jodi ByersDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Glenna J PetersonDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Kevin P FennellyDivision of Intramural Research, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, Maryland, USA.
Videlis NdubaCentre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID https://orcid.org/0000-0002-2266-8349
David J HorneDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Jerry S ZifodyaDepartment of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Thomas R HawnDepartment of Medicine, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-2368-3185

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Aerobiology, immunology, and Mycobacterium tuberculosis transmissionR01AI150815 · NIAID · UNIVERSITY OF WASHINGTON · PI HAWN, THOMAS R, HORNE, DAVID J. · 2020 to 2024
$3.5M
Tuberculosis & HIV Co-Infection Training Program in KenyaD43TW011817 · FIC · UNIVERSITY OF WASHINGTON · PI Thomas R Hawn, VIDELIS NDUBA · 2021 to 2026
$1.6M
Clinical and biologic risk factors for post-tuberculosis lung disease (PTLD) in people with and without HIVK23HL164289 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI Jerry S. Zifodya · 2022 to 2026
$893k
Mycobacterium tuberculosis aerobiology and novel tools to assess infectiousnessUH2AI152621 · NIAID · UNIVERSITY OF WASHINGTON · PI HORNE, DAVID J. · 2021 to 2022
$365k
FIC NIH HHS D43 TW011817NCATS NIH HHS UL1 TR002319NHLBI NIH HHS K23 HL164289NIAID NIH HHS R01 AI150815NIAID NIH HHS UH2 AI152621
6 · The paper itself

Abstract

Background: Post-tuberculosis (TB) lung disease (PTLD) affects ∼50% of persons with pulmonary TB (PTB). We recently discovered whole blood transcriptional signatures associated with PTLD. We examined whether a minimum gene signature predicts PTLD as a clinically useful biomarker. Methods: We prospectively enrolled 301 treatment naive adults with newly diagnosed PTB (cohort A). We collected whole blood at 0 and 6-month visits, isolated RNA, and measured a modified MTB host response (HR) signature (mHR) based on expression of DUSP3, GBP5, and TMBIM6. We recorded spirometry at 6 ( Results: mHR was associated with TB ( Conclusions: Baseline mHR was associated with obstructive PTLD at 6 and 12 months and may have applications in targeting treatment and prognostication.

Indexed as

host immune responsepost-tuberculosis lung diseasetuberculosis

Identifiers

PMID42898833
PMCPMC13678225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.